Modeling the budget impact of long-acting injectable paliperidone palmitate in the treatment of schizophrenia in Japan

References

• MontgomeryWLiuLStenslandMDXueHBTreuerTAscher-SvanumHThe personal, societal, and economic burden of schizophrenia in the People’s Republic of China: implications for antipsychotic therapyClinicoecon Outcomes Res201314540741823983478
   PubMedGoogle Scholar
• SadoMInagakiAKorekiAThe cost of schizophrenia in JapanNeuropsychiatr Dis Treat2013978779823785238
   PubMed Web of Science ®Google Scholar
• van OsJKapurSSchizophreniaLancet2009374969063564519700006
   PubMed Web of Science ®Google Scholar
• LinIMuserEMunsellMBensonCMenzinJEconomic impact of psychiatric relapse and recidivism among adults with schizophrenia recently released from incarceration: a Markov model analysisJ Med Econ201426111
   Google Scholar
• FitchKIwasakiKVillaKResource utilization and cost in a commercially insured population with schizophreniaAm Health Drug Benefits201471182624991388
   PubMedGoogle Scholar
• FreySThe economic burden of schizophrenia in Germany: a population-based retrospective cohort study using genetic matchingEur Psychiatry201429847948924853296
   PubMed Web of Science ®Google Scholar
• HigashiKMedicGLittlewoodKJDiezTGranströmODe HertMMedication adherence in schizophrenia: factors influencing adherence and consequences of nonadherence, a systematic literature reviewTher Adv Psychopharmacol20133420021824167693
   PubMedGoogle Scholar
• PengXAscher-SvanumHFariesDConleyRSchuhKDecline in hospitalization risk and health care cost after initiation of depot antipsychotics in the treatment of schizophreniaClinicoecon Outcomes Res2011391421935327
   PubMedGoogle Scholar
• AcostaFJBoschESarmientoGJuanesNCaballero-HidalgoAMayansTEvaluation of noncompliance in schizophrenia patients using electronic monitoring (MEMS) and its relationship to sociodemographic, clinical and psychopathological variablesSchizophr Res2009107221321718849150
   PubMed Web of Science ®Google Scholar
• WillisMSvenssonMLöthgrenMErikssonBBerntssonAPerssonUThe impact of schizophrenia-related hospital utilization and cost of switching to long-acting risperidone injections in SwedenEur J Health Econ201011658559420084535
   PubMed Web of Science ®Google Scholar
• TiihonenJHaukkaJTaylorMHaddadPMPatelMXKorhonenPA nationwide cohort study of oral and depot antipsychotics after first hospitalization for schizophreniaAm J Psychiatry2011168660360921362741
   PubMed Web of Science ®Google Scholar
• Grimaldi-BensoudaLRouillonFAstrucBCGS Study GroupDoes longacting injectable risperidone make a difference to the real-life treatment of schizophrenia? Results of the cohort for the general study of schizophrenia (CGS)Schizophr Res20121342–318719422130111
   PubMed Web of Science ®Google Scholar
• LeuchtCHeresSKaneJMKisslingWDavisJMLeuchtSOral versus depot antipsychotic drugs for schizophrenia – a critical systematic review and meta-analysis of randomised long-term trialsSchizophr Res20111271–3839221257294
   PubMed Web of Science ®Google Scholar
• GaebelWSchreinerABergmansPRelapse prevention in schizophrenia and schizoaffective disorder with risperidone long-acting injectable vs quetiapine: results of a long-term, open-label, randomized clinical trialNeuropsychopharmacology2010352367237720686456
   PubMed Web of Science ®Google Scholar
• SpillBKonoppaSKisslingWMainoKMesserTHeresSLong-term observation of patients successfully switched to risperidone long-acting injectable: a retrospective, naturalistic 18-month mirror-image study of hospitalization rates and therapy costsInt J Psychiatry Clin Pract201014536224917233
   PubMed Web of Science ®Google Scholar
• LauxGHeegBvan HoutBMehnertACosts and effects of long-acting risperidone compared with oral atypical and conventional depot formulations in GermanyPharmacoeconomics200523Suppl 1496116416761
   PubMed Web of Science ®Google Scholar
• OlivaresJMRodriguez-MoralesADielsJe-STAR Spanish Study GroupLong-term outcomes in patients with schizophrenia treated with risperidone long-acting injection or oral antipsychotics in Spain: results from the electronic Schizophrenia Treatment Adherence Registry (e-STAR)Eur Psychiatry200924528729619195847
   PubMed Web of Science ®Google Scholar
• ZeidlerJMahlichJGreinerWHeresSCost-effectiveness of paliperidone palmitate for the treatment of schizophrenia in GermanyAppl Health Econ Health Policy201311550952123975630
   PubMedGoogle Scholar
• MehnertANichollDPudasHMartinMMcGuireACost-effectiveness of paliperidone palmitate versus risperidone long-acting injectable and olanzapine pamoate for the treatment of patients with schizophrenia in SwedenJ Med Econ201215584486122458756
   PubMedGoogle Scholar
• OlivaresJMRodriguez-MartinezABurónJAAlonso-EscolanoDRodriguez-MoralesAe-STAR Study GroupCost-effectiveness analysis of switching antipsychotic medication to longacting injectable risperidone in patients with schizophrenia: a 12- and 24-month follow-up from the e-STAR database in SpainAppl Health Econ Health Policy200861415318774869
   PubMedGoogle Scholar
• EinarsonTRVicenteCZilbershteinRPharmacoeconomic analysis of paliperidone palmitate versus olanzapine pamoate for chronic schizophrenia in NorwayActa Neuropsychiatr2013252859425287309
   PubMed Web of Science ®Google Scholar
• EinarsonTRGeitonaMChaidemenosAPharmacoeconomic analysis of paliperidone palmitate for treating schizophrenia in GreeceAnn Gen Psychiatry2012111822747533
   PubMed Web of Science ®Google Scholar
• KimBLeeTJWooJMCost-utility analysis of paliperidone palmitate long acting injection (PLAI) vs oral at ypical antipsychotics in non-adherent schizophrenia patientsKorean J Psychopharmacol2012231727
   Google Scholar
• JoshiKLinJLingohr-SmithMFuDJEstimated medical cost reductions for paliperidone palmitate versus placebo in a randomized, double-blind relapse-prevention trial of patients with schizoaffective disorderJ Med Econ20152312225800457
   PubMed Web of Science ®Google Scholar
• RansmeyrSMehnertAMahlichJBudget Impact Analyse von Paliperidon Palmitat im österreichischen Versorgungskontext [Budget impact analysis of paliperdidone palmitate in the Austrian health care system]PharmacoEconomics German Research Articles2013112532
   Google Scholar
• Statistics JapanCurrent Population EstimatesTokyo2013 Available from: http://www.stat.go.jp/english/data/jinsui/2013np/index.htmAccessed December 15, 2014
   Google Scholar
• Ministry of Health, Labor WelfarePatient Survey (Kanja Chosa)Tokyo2011 Available from: http://www.mhlw.go.jp/toukei/saikin/hw/kanja/11/index.htmlAccessed December 15, 2014
   Google Scholar
• Hokenyakujiten Plus+The Edition of April 2013TokyoJiho2013
   Google Scholar
• Hokenyakujiten Plus+The Edition of April 2014TokyoJiho2014
   Google Scholar
• GrabowskiHVernonJLonger patents for increased generic competition: the Waxman-Hatch act after on e decadePharmacoeconomics19961011012310163428
   PubMed Web of Science ®Google Scholar
• JakovljevicMBNakazonoSOguraSContemporary generic market in Japan – key conditions to successful evolutionExpert Rev Pharmacoecon Outcomes Res201414218119424450984
   PubMed Web of Science ®Google Scholar
• IizukaTKuboKThe generic drug market in Japan: will it finally take off?Health Econ Policy Law20116336938921205400
   PubMed Web of Science ®Google Scholar
• WaddellLTaylorMAttitudes of patients and mental health staff to antipsychotic long-acting injections: systematic reviewBr J Psychiatry2009195s43s50
   Web of Science ®Google Scholar
• SamalinLCharpeaudTBlancOHeresSLlorcaPMClinicians’ attitudes toward the use of long-acting injectable antipsychoticsJ Nerv Ment Dis2013201755355923817151
   PubMed Web of Science ®Google Scholar
• KuwabaraHSaitoYMahlichJAdherence and re-hospitalizations in patients with schizophrenia: evidence from Japanese claims dataNeuropsychiatr Dis Treat20151193594025897229
   PubMed Web of Science ®Google Scholar
• National Collaborating Centre for Mental HealthSchizophreniaThe NICE Guideline on Core Interventions in the Treatment and Management of Schizophrenia in Adults in Primary and Secondary CareLondonThe British Psychological Society and The Royal College of Psychiatrists2010
   Google Scholar
• LeuchtSCorvesCArbterDEngelRLiCDavisJSecond-generation versus first-generation antipsychotic drugs for schizophrenia: a meta-analysisLancet2009373314119058842
   PubMed Web of Science ®Google Scholar
• FuDJTurkozISimonsonBRPaliperidone palmitate once-monthly reduces risk of relapse of psychotic, depressive, and manic symptoms and maintains functioning in a double-blind, randomized study of schizoaffective disorderJ Clin Psychiatry201576325326225562685
   PubMed Web of Science ®Google Scholar
• KishiTMatsudaYNakamuraHIwataNBlonanserin for schizophrenia: systematic review and meta-analysis of double-blind, randomized, controlled trialsJ Psychiatr Res201347149e15423131856
   PubMed Web of Science ®Google Scholar
• TenjinTMiyamotoSNinomiyaYProfile of blonanserin for the treatment of schizophreniaNeuropsychiatr Dis Treat2013958759423766647
   PubMed Web of Science ®Google Scholar
• Statistics Bureau, Ministry of Internal affairs and CommunicationsShouhishabukkashisu (Consumer Price Index)Tokyo2014 Available from: http://www.stat.go.jp/data/cpi/index.htmAccessed December 15, 2014
   Google Scholar
• SadoMInagakiAKorekiASeishin shikkan no syakaiteki cost(kosuto) no suikei. Estimation of Social Costs of Mental DiseasesTokyoKeio University2011 Available from: http://www.mhlw.go.jp/bunya/shou-gaihoken/cyousajigyou/dl/seikabutsu30-2.pdf#search='%E7%B2%BE%E7%A5%9E%E7%96%BE%E6%82%A3%E3%81%AE%E7%A4%BE%E4%BC%9A%E7%9A%84%E3%82%B3%E3%82%B9%E3%83%88'Accessed December 15, 2014
   Google Scholar
• Ministry of FinanceInterest RateTokyo2015 Available from: http://www.mof.go.jp/english/jgbs/reference/interest_rate/index.htmAccessed December 15, 2014
   Google Scholar
• Ascher-SvanumHZhuBFariesDThe cost of relapse and the predictors of relapse in the treatment of schizophreniaBMC Psychiatry201010220059765
   PubMed Web of Science ®Google Scholar
• MangaloreRKnappMCost of schizophrenia in EnglandJ Ment Health Policy Econ2007101234117417045
   PubMed Web of Science ®Google Scholar
• MoriwakiKNeunerTHübner-LiebermannBAcute psychiatric inpatient care: a cross-cultural comparison between two hospitals in Germany and JapanInt J Soc Psychiatry201359877178123034283
   PubMed Web of Science ®Google Scholar
• OshimaIMinoYInomataYInstitutionalisation and schizophrenia in Japan: social environments and negative symptoms nationwide survey of in-patientsBr J Psychiatry2003183505612835244
   PubMed Web of Science ®Google Scholar
• SugibayashiYYoshimuraKYamauchiKInagakiAIkegamiNInfluence of patient characteristics on care time in patients hospitalized with schizophreniaNeuropsychiatr Dis Treat2014101577158425187720
   PubMed Web of Science ®Google Scholar
• OshimaIMinoYInmataYHow many long-stay schizophrenia patients can be discharged in Japan?Psychiatry Clin Neurosci200761717717239042
   PubMed Web of Science ®Google Scholar
• ZeidlerJHeresSMahlichJGreinerWTreatment patterns and costs in patients with schizophrenia in GermanyValue Health2012157A336A337
   Google Scholar
• HeresSSchmitzFSLeuchtSPajonkFGThe attitude of patients towards antipsychotic depot treatmentInt Clin Psychopharmacol200722527528217690596
   PubMed Web of Science ®Google Scholar